C. , CASyM and the road to Systems Medicine, 2015.

B. R. Iyengar, R. B. Altman, O. G. Troyanskaya, and G. A. Fitzgerald, Experimentation Can Enable Precision Medicine, Science, vol.350, issue.6258, pp.282-283, 2015.

O. Wolkenhauer, C. Auffray, O. Brass, J. Clairambault, A. Deutsch et al., Enabling multiscale modeling in systems medicine, Genome Medicine, vol.6, issue.3, pp.4-6, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01109002

A. Anderson and V. Quaranta, Integrative mathematical oncology, Nature Reviews Cancer, vol.8, issue.3, pp.227-234, 2008.

Z. Agur, M. Elishmereni, and Y. Kheifetz, Personalizing oncology treatments by predicting drug efficacy, sideeffects, and improved therapy: Mathematics, statistics, and their integration, Wiley Interdisciplinary Reviews: Systems Biology and Medicine, vol.6, issue.3, pp.239-253, 2014.

J. P. Boissel, C. Auffray, D. Noble, L. Hood, and F. H. Boissel, Bridging systems medicine and patient needs, CPT: Pharmacometrics and Systems Pharmacology, vol.4, issue.3, pp.135-145, 2015.

K. K. Giuliano and C. Niemi, The urgent need for innovation in I.V. infusion devices, Nursing, vol.46, issue.4, pp.66-68, 2016.

D. L. Hertz and R. J. , Pharmacogenetics of Cancer Drugs, Annual Review of Medicine, vol.66, issue.1, pp.65-81, 2015.

S. E. Jackson and J. D. Chester, Personalised cancer medicine, International Journal of Cancer, vol.137, issue.2, pp.262-266, 2015.

A. Paci, G. Veal, C. Bardin, D. Levêque, N. Widmer et al., Review of therapeutic drug monitoring of anticancer drugs part 1-Cytotoxics, European Journal of Cancer, vol.50, issue.12, pp.2010-2019, 2014.

A. Ballesta, P. F. Innominato, R. Dallmann, D. A. Rand, and F. A. Lévi, Systems Chronotherapeutics. Pharmacological Reviews, vol.69, issue.2, pp.161-199, 2017.

F. Lé-vi, C. Focan, A. Karaboué, V. De-la-valette, D. Focan-henrard et al., Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Advanced Drug Delivery Reviews, vol.59, pp.1015-1035, 2007.

R. Dallmann, A. Okyar, and F. Lé-vi, Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy, Trends in Molecular Medicine, vol.22, issue.5, pp.430-445, 2016.

P. F. Innominato, F. A. Lé-vi, and G. A. Bjarnason, Chronotherapy and the molecular clock: Clinical implications in oncology, Advanced Drug Delivery Reviews, vol.62, issue.9, pp.979-1001, 2010.

F. Levi, A. Okyar, S. Dulong, P. F. Innominato, J. Clairambault et al., Circadian timing in cancer treatments. Annual review of pharmacology and toxicology, vol.50, pp.377-421, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00780807

S. Giacchetti, P. A. Dugué, P. F. Innominato, G. A. Bjarnason, C. Focan et al., Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: A meta-analysis, Annals of Oncology, vol.23, issue.12, pp.3110-3116, 2012.

X. M. Li, A. Mohammad-djafari, M. Dumitru, S. Dulong, E. Filipski et al., A circadian clock transcription model for the personalization of cancer chronotherapy, Cancer Research, vol.73, issue.24, pp.7176-7188, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00935081

F. Levi, C. Garufi, A. Karaboué, C. Focan, P. Chollet et al., Sex-related differences in circadiandependent tolerance of Irinotecan (I) added to chronomodulated (chrono) 5-Fluorouracil (F), Annals of Oncology, vol.28, issue.suppl_5, 2017.

E. Ortiz-tudela, P. F. Innominato, M. A. Rol, F. Lévi, and J. A. Madrid, Relevance of internal time and circadian robustness for cancer patients, BMC Cancer, vol.16, issue.1, p.27102330, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01322554

F. Lé-vi, A. Karaboué, E. Mc, G. Paintaud, C. Focan et al., Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study, Clinical Pharmacokinetics, pp.1-13, 2016.

L. C. Evans, Graduate studies in mathematics, Society AM. Partial Differential Equations, 1998.

C. R. Culy, D. Clemett, and L. R. Wiseman, Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies, Drugs, vol.60, issue.4, pp.895-924, 2000.

S. P. Joel, D. Papamichael, F. Richards, T. Davis, V. Aslanis et al., Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin, Clinical Pharmacology & Therapeutics, vol.76, issue.1, pp.45-54, 2004.

R. P. Riechelmann and E. D. Saad, A systematic review on drug interactions in oncology, Cancer Investigation, vol.24, issue.7, pp.704-712, 2006.

J. N. Vauthey, E. K. Abdalla, D. A. Doherty, P. Gertsch, M. J. Fenstermacher et al., Body surface area and body weight predict total liver volume in western adults, Liver Transplantation, vol.8, issue.3, pp.233-240, 2002.

S. B. Nadler, J. U. Hidalgo, and T. Bloch, Prediction of blood volume in normal human adults, Surgery, vol.51, issue.2, pp.224-232, 1962.

J. Sendroy and H. A. Collison, Determination of human body volume from height and weight, Journal of Applied Physiology, vol.21, issue.1, pp.167-172, 1966.

M. A. Graham, G. F. Lockwood, D. Greenslade, S. Brienza, M. Bayssas et al., Clinical Pharmacokinetics of Oxaliplatin: A Critical Review. Clinical Cancer Research, vol.18, issue.1, pp.1205-1218, 2000.

J. G. Slatter, L. J. Schaaf, J. P. Sams, K. L. Feenstra, M. G. Johnson et al., Metabolism, and Excretion of Irinotecan (Cpt-11) following I. V. Infusion of [14C]Cpt-11 in Cancer Patients, Drug Metabolism and Disposition, vol.28, issue.4, pp.423-433, 2000.

B. Schilsky, Biochemical and Clinical Pharmacology of 5-Fluorouracil Cellular Determinants of Sensitivity to Fluoropyrimidines, Oncology, vol.12, issue.7, pp.13-18, 1998.

N. A. Boughattas, F. Levi, C. Fournier, G. Lemaigre, A. Roulon et al., Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice, Cancer Research, vol.49, issue.12, pp.3362-3368, 1989.

D. Wang, L. Zou, J. Q. Hou, J. Ge, G. Yang et al., Human carboxylesterases: a comprehensive review, Acta Pharmaceutica Sinica B, vol.8, issue.5, pp.699-712, 2018.

L. P. Rivory, M. R. Bowles, J. Robert, and S. M. Pond, Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38) by human liver carboxylesterase, Biochemical Pharmacology, vol.52, issue.7, pp.1103-1111, 1996.

A. Ahluwalia, Allometric scaling in-vitro, Scientific Reports, vol.7, p.42113, 2017.

Y. Tsukamoto, Y. Kato, M. Ura, I. Horii, H. Ishitsuka et al., A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: The mechanism for tumor-selective accumulation of 5-FU, Pharmaceutical Research, vol.18, issue.8, pp.1190-1202, 2001.

O. Combes, J. Barré, J. C. Duché, L. Vernillet, Y. Archimbaud et al., In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood, Investigational New Drugs, vol.18, issue.1, pp.1-5, 2000.

A. Ballesta, S. Dulong, C. Abbara, B. Cohen, A. Okyar et al., A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery, PLoS Computational Biology, vol.7, issue.9, pp.1-12, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00692053

C. Bertucci, G. Ascoli, G. Uccello-barretta, D. Bari, L. Salvadori et al., The binding of 5-fluorouracil to native and modified human serum albumin: UV, CD, and 1H and 19F NMR investigation, vol.13, pp.1087-93, 1995.

. Pfizer, CAMPTOSAR (Irinotecan) HIGHLIGHTS OF PRESCRIBING INFORMATION, 2014.

W. Wang and Y. Zhang, On fuzzy cluster validity indices. Fuzzy Sets and Systems, vol.158, pp.2095-2117, 2007.

L. Deyme, D. Barbolosi, and F. Gattacceca, Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters, Cancer Chemotherapy and Pharmacology, vol.83, issue.1, p.30446786, 2019.

F. A. Lé-vi, V. Boige, M. Hebbar, D. Smith, C. Lepère et al., Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV, Annals ofOncology, vol.27, pp.267-274, 2015.

F. Lé-vi, A. Karaboué, R. Saffroy, C. Desterke, V. Boige et al., Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228), British Journal of Cancer, vol.117, issue.7, pp.965-973, 2017.

E. Jones, T. Oliphant, P. Peterson, and . Others, {SciPy}: Open source scientific tools for {Python}, 2001.

S. Basu, M. Zeng, T. Yin, S. Gao, and M. Hu, Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, pp.34-41, 2016.

B. N. Matos, P. Oliveira, T. A. Reis, T. Gratieri, M. Cunha-filho et al., Development and Validation of a Simple and Selective Analytical HPLC Method for the Quantification of Oxaliplatin, Journal of Chemistry, 2015.

M. Hayat, M. Sohail, M. Ashraf, and M. , Spectrophotometric determination of cisplatin, carboplatin and oxaliplatin in pure and injectable dosage forms, Biomedical Research, vol.30, issue.4, pp.557-562, 2019.

B. Sendhoff, Covariance Matrix Adaptation Revisited-the CMSA Evolution Strategy -. International Conference on Parallel Problem Solving from Nature, vol.3242, 2008.

Z. Xy, M. N. Trame, L. J. Lesko, and S. Schmidt, Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models. CPT: pharmacometrics & systems pharmacology, vol.4, pp.69-79, 2015.

A. Raue, C. Kreutz, T. Maiwald, J. Bachmann, U. Klingmü-ller et al., Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood, Bioinformatics, vol.25, issue.15, pp.1923-1929, 2009.

D. Kang, J. B. Schwartz, and D. Verotta, Sample Size Computations for PK / PD Population Models, Journal of Pharmacokinetics and Pharmacodynamics, vol.32, issue.5-6, pp.685-701, 2005.

K. Ogungbenro, L. Aarons, K. Ogungbenro, and L. Aarons, Sample Size / Power Calculations for Population Pharmacodynamic Experiments Involving Repeated-Count Measurements, Journal of Biopharmaceutical Statistics ISSN, vol.20, issue.5, pp.1026-1042, 2010.

F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion et al., Scikit-learn: Machine Learning in {P}ython, Journal of Machine Learning Research, vol.12, pp.2825-2830, 2011.

N. Jaworska and A. C. Anastasova, A Review of Multidimensional Scaling (MDS) and its Utility in Various Psychological Domains, Tutorials in Quantitative Methods for Psychology, vol.5, issue.1, 2009.